Search clinical trials for: 18F-DTBZ AV-133

Total 165 results

Chang Gung Memorial Hospital

Completed

Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression

Parkinson Disease
Chang Gung Memorial Hospital

Completed

Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects

Healthy
Yale University
Pfizer; Avid Radiopharmaceuticals

Completed

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

Diabetes Mellitus, Type 1

United States
Avid Radiopharmaceuticals

Completed

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Parkinson's Disease | Alzheimer's Disease | Dementia With Lewy Bodies

United States
Avid Radiopharmaceuticals

Terminated

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

Type 1 Diabetes | Type 2 Diabetes

United States
Avid Radiopharmaceuticals

Completed

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

Parkinson's Disease | Primary Parkinsonism | Lewy Body Parkinson's Disease

United States, Australia
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Avid Radiopharmaceuticals

Completed

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Tauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Tammie L. S. Benzinger, MD, PhD

Withdrawn

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 High Resolution Autopsy Study

Alzheimer's Disease

United States
Tammie L. S. Benzinger, MD, PhD

Recruiting

F 18 T807 Tau PET Imaging of Alzheimer's Disease (T807IND)

Alzheimer Disease

United States
Washington University School of Medicine

Enrolling by invitation

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) (AV ADAD)

Alzheimer Disease

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) (Protocol E)

Alzheimer Disease | Progressive Posterior Cortical Dysfunction (PPCD)

United States
Avid Radiopharmaceuticals

Withdrawn

18F-AV-1451 PET Imaging in TBI

Traumatic Brain Injury

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

Alzheimer Disease | HIV

United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism

Vascular Parkinsonism

Taiwan
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism

Parkinson's Disease

Taiwan
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Completed

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD) | Significant Memory Concern (SMC) | Early Mild Cognitive Impairment (EMCI) | Late Mild Cognitive Impairment (LMCI)

United States, Canada
Chang Gung Memorial Hospital

Completed

Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism

Parkinson's Disease

Taiwan
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET

Parkinson's Disease

Taiwan
Chang Gung Memorial Hospital

Completed

18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging (8F-DTBZ)

Parkinson's Disease

Taiwan
Tammie L. S. Benzinger, MD, PhD

Withdrawn

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers. (Protocol_Z)

Alzheimer Disease

United States
Avid Radiopharmaceuticals
Pfizer

Completed

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

Type 2 Diabetes

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Chang Gung Memorial Hospital

Unknown

Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication

Carbon Monoxide-induced Parkinsonism

Taiwan
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (T807ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Avid Radiopharmaceuticals

Completed

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

Alzheimer Disease

United States

Search clinical trials for: 18F-DTBZ AV-133

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations